<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Clinical Trials on VXB US</title>
    <link>https://www.vxbus.com/tags/clinical-trials/</link>
    <description>Recent content in Clinical Trials on VXB US</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en</language>
    <copyright>© 2026 </copyright>
    <lastBuildDate>Sat, 07 Feb 2026 11:58:26 +0800</lastBuildDate><atom:link href="https://www.vxbus.com/tags/clinical-trials/index.xml" rel="self" type="application/rss+xml" />
    
    <item>
      <title>Bayer’s Asundexian Cuts Recurrent Stroke Risk by 26% in Phase 3 Trial</title>
      <link>https://www.vxbus.com/news/bayers-asundexian-cuts-recurrent-stroke-risk-by-26-percent-in-phase-3-trial/</link>
      <pubDate>Sat, 07 Feb 2026 11:58:26 +0800</pubDate>
      
      <guid>https://www.vxbus.com/news/bayers-asundexian-cuts-recurrent-stroke-risk-by-26-percent-in-phase-3-trial/</guid>
      <description></description>
      <media:content xmlns:media="http://search.yahoo.com/mrss/" url="https://www.vxbus.com/news/bayers-asundexian-cuts-recurrent-stroke-risk-by-26-percent-in-phase-3-trial/featured-Bayer-Asundexian-Cuts-Recurrent-Stroke.png" />
    </item>
    
    <item>
      <title>Why Alzheimer’s Trials Must Address Sex Differences</title>
      <link>https://www.vxbus.com/news/why-alzheimers-trials-must-address-sex-differences/</link>
      <pubDate>Tue, 30 Dec 2025 22:43:12 +0800</pubDate>
      
      <guid>https://www.vxbus.com/news/why-alzheimers-trials-must-address-sex-differences/</guid>
      <description></description>
      <media:content xmlns:media="http://search.yahoo.com/mrss/" url="https://www.vxbus.com/news/why-alzheimers-trials-must-address-sex-differences/featured-Why-Sex-Matters-in-Alzheimer%E2%80%99s.png" />
    </item>
    
    <item>
      <title>Sanofi’s AlphaMedix Hits Key Efficacy Goals in Phase 2 Neuroendocrine Tumor Trial</title>
      <link>https://www.vxbus.com/news/sanofis-alphamedix-hits-key-efficacy-goals-in-phase-2-neuroendocrine-tumor-trial/</link>
      <pubDate>Thu, 09 Oct 2025 20:08:06 +0800</pubDate>
      
      <guid>https://www.vxbus.com/news/sanofis-alphamedix-hits-key-efficacy-goals-in-phase-2-neuroendocrine-tumor-trial/</guid>
      <description></description>
      <media:content xmlns:media="http://search.yahoo.com/mrss/" url="https://www.vxbus.com/news/sanofis-alphamedix-hits-key-efficacy-goals-in-phase-2-neuroendocrine-tumor-trial/featured-Sanofi-AlphaMedix.png" />
    </item>
    
    <item>
      <title>How AI and Data are Shaping the Future of Inclusive Clinical Trials</title>
      <link>https://www.vxbus.com/news/how-ai-and-data-are-shaping-the-future-of-inclusive-clinical-trials/</link>
      <pubDate>Mon, 22 Sep 2025 12:14:09 +0800</pubDate>
      
      <guid>https://www.vxbus.com/news/how-ai-and-data-are-shaping-the-future-of-inclusive-clinical-trials/</guid>
      <description></description>
      <media:content xmlns:media="http://search.yahoo.com/mrss/" url="https://www.vxbus.com/news/how-ai-and-data-are-shaping-the-future-of-inclusive-clinical-trials/featured-AI-Data-Shap-the-Future-of-inclusive-clinical-trials.png" />
    </item>
    
  </channel>
</rss>
